Low Grade Glioma Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Day One Biopharma, Servier, SpringWorks Therapeutics, AnHeart Therapeutic, Beigene

Low Grade Glioma Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Day One Biopharma, Servier, SpringWorks Therapeutics, AnHeart Therapeutic, Beigene
“Low Grade Glioma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Low Grade Glioma, historical and forecasted epidemiology as well as the Low Grade Glioma market trends in the 7MM.

DelveInsight’s “Low Grade Glioma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Low Grade Glioma, historical and forecasted epidemiology as well as the Low Grade Glioma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Low Grade Glioma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Low Grade Glioma Market Forecast

 

Some of the key facts of the Low Grade Glioma Market Report: 

  • The Low Grade Glioma market size was valued approximately USD 1 billion in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • The anticipated introduction of prospective treatments such as Day One Biopharmaceuticals’ (DAY101), AnHeart Therapeutic’s (AB218), SpringWorks Therapeutics’ (mirdametinib), Servier’s (vorasidenib [AG- 881]), and additional therapies is likely to contribute to the potential expansion of the market size in the upcoming years.
  • In June 2022, Day One Biopharmaceuticals disclosed encouraging initial findings from its pivotal Phase II trial (FIREFLY-1) assessing tovorafenib (DAY101) in pediatric patients experiencing recurrence of low-grade glioma (pLGG).
  • As per the GLOBOCAN 2020 estimates, there were 308,102 newly reported cases of brain and central nervous system tumors worldwide in 2020, showing a higher incidence rate in developed nations.
  • In 2022, the collective new cases of Low-grade Gliomas (LGG) across the 7MM totaled around 9,000 and are expected to rise in the forecasted period.
  • In 2022, the United States reported a nearly 4,000-strong incident population of Low-grade Gliomas (LGG), representing roughly 40% of the total incident population across the 7MM.
  • In 2022, among the EU4 nations and the UK, Germany exhibited the highest diagnosed prevalence of Low-grade Gliomas (LGG), followed by France. Spain, on the other hand, reported the lowest number of cases within this category.
  • Key Low Grade Glioma Companies: Day One Biopharmaceuticals, Servier, SpringWorks Therapeutics, AnHeart Therapeutics, Beigene, Helsinn, Forma Therapeutics, Hoffmann-La Roche, and others
  • Key Low Grade Glioma Therapies: Tovorafenib (DAY101), Vorasidenib, Mirdametinib, AB-218, BGB-290, Infigratinib, FT-2102 (Olutasidenib), Vinblastine + Bevacizumab, and others
  • The Low Grade Glioma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Low Grade Glioma pipeline products will significantly revolutionize the Low Grade Glioma market dynamics.

 

Low Grade Glioma Overview

Low-grade Gliomas (LGG) constitute a diverse category of primary brain tumors commonly found in younger, otherwise healthy individuals. Typically, these tumors exhibit a relatively slow progression and extended survival rates compared to high-grade gliomas.

 

Get a Free sample for the Low Grade Glioma Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/low-grade-glioma-market

 

Low Grade Glioma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Low Grade Glioma Epidemiology Segmentation:

The Low Grade Glioma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Low Grade Glioma
  • Prevalent Cases of Low Grade Glioma by severity
  • Gender-specific Prevalence of Low Grade Glioma
  • Diagnosed Cases of Episodic and Chronic Low Grade Glioma

 

Download the report to understand which factors are driving Low Grade Glioma epidemiology trends @ Low Grade Glioma Epidemiology Forecast

 

Low Grade Glioma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Low Grade Glioma market or expected to get launched during the study period. The analysis covers Low Grade Glioma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Low Grade Glioma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Low Grade Glioma Therapies and Key Companies

  • Tovorafenib (DAY101): Day One Biopharmaceuticals
  • Vorasidenib: Servier
  • Mirdametinib: SpringWorks Therapeutics
  • AB-218: AnHeart Therapeutics
  • BGB-290: Beigene
  • Infigratinib: Helsinn
  • FT-2102 (Olutasidenib): Forma Therapeutics
  • Vinblastine + Bevacizumab: Hoffmann-La Roche, and others

 

Discover more about therapies set to grab major Low Grade Glioma market share @ Low Grade Glioma Treatment Landscape

 

Low Grade Glioma Market Strengths

  • Low Grade Glioma is a rare form is glioma; thus, companies developing treatment options for the same can possess several advantages like market exclusivities, premium pricing, subsidy for conducting trials, and several other benefits from the government bodies for R&D.

 

Low Grade Glioma Market Opportunities

  • Newer imaging techniques, such as MR spectroscopy (MRS) and positron emission tomography (PET) imaging, may improve the diagnostic potential, challenges exist in the ability for conventional MRI to distinguish between primary tumours versus metastases and CNS masses, and true progression versus pseudo progression.

 

Scope of the Low Grade Glioma Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Low Grade Glioma Companies: Day One Biopharmaceuticals, Servier, SpringWorks Therapeutics, AnHeart Therapeutics, Beigene, Helsinn, Forma Therapeutics, Hoffmann-La Roche, and others
  • Key Low Grade Glioma Therapies: Tovorafenib (DAY101), Vorasidenib, Mirdametinib, AB-218, BGB-290, Infigratinib, FT-2102 (Olutasidenib), Vinblastine + Bevacizumab, and others
  • Low Grade Glioma Therapeutic Assessment: Low Grade Glioma current marketed and Low Grade Glioma emerging therapies
  • Low Grade Glioma Market Dynamics: Low Grade Glioma market drivers and Low Grade Glioma market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Low Grade Glioma Unmet Needs, KOL’s views, Analyst’s views, Low Grade Glioma Market Access and Reimbursement 

 

To know more about Low Grade Glioma companies working in the treatment market, visit @ Low Grade Glioma Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Low Grade Glioma Market Report Introduction

2. Executive Summary for Low Grade Glioma

3. SWOT analysis of Low Grade Glioma

4. Low Grade Glioma Patient Share (%) Overview at a Glance

5. Low Grade Glioma Market Overview at a Glance

6. Low Grade Glioma Disease Background and Overview

7. Low Grade Glioma Epidemiology and Patient Population

8. Country-Specific Patient Population of Low Grade Glioma 

9. Low Grade Glioma Current Treatment and Medical Practices

10. Low Grade Glioma Unmet Needs

11. Low Grade Glioma Emerging Therapies

12. Low Grade Glioma Market Outlook

13. Country-Wise Low Grade Glioma Market Analysis (2019–2032)

14. Low Grade Glioma Market Access and Reimbursement of Therapies

15. Low Grade Glioma Market Drivers

16. Low Grade Glioma Market Barriers

17.  Low Grade Glioma Appendix

18. Low Grade Glioma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/


Posted

in

by

Tags: